IP Library Granted Patent US 7,910,368
Granted Patent B2
US 7,910,368 · App. 10/486,512 · Granted Mar 22, 2011

Method of extended culture for antigen-specific cytotoxic lymphocytes

Assignee: Takara Bio Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,910,368
App. No.
10/486,512
Granted
Mar 22, 2011
Kind
B2
Abstract

The present invention is a method for inducing cytotoxic T cell having an antigen-specific cytotoxic activity, a method for maintaining the cell, a method for continuously culturing the cell or a method for expanding the cell, comprising the step of culturing a cytotoxic T cell in the presence of at least one substance selected from the group consisting of (A) a substance having a binding activity to CD44; (B) a substance capable of regulating a signal emitted by binding a CD44 ligand to CD44; (C) a substance capable of inhibiting binding of a growth factor to a growth factor receptor; (D) a substance capable of regulating a signal emitted by binding of a growth factor to a growth factor receptor; and (E) fibronectin, a fragment thereof or a mixture thereof.

Claims (21)

1. A method for maintaining cytotoxic T cell having an antigen-specific cytotoxic activity, characterized in that the method comprises the steps of:

incubating a peripheral blood mononuclear cell with an antigen presenting cell in a medium containing effective ingredients consisting essentially of interleukin-2 and a fragment of fibronectin having a molecular weight of from 10 kDa to 180 kDa or a mixture thereof, wherein the fragment of fibronectin is immobilized to an artificial substrate and comprises at least one domain selected from the group consisting of (a) a VLA-4 binding domain (b) a VLA-5 binding domain and (c) a heparin binding domain, and said incubating step gives said peripheral blood mononuclear cell an ability to recognize a desired antigen and induces differentiation of the peripheral mononuclear cell to a cytotoxic T cell; and

continuously culturing the cytotoxic T cell obtained by the preceding step in the presence of a fragment of fibronectin having a molecular weight of from 10 kDa to 180 kDa or a mixture thereof, wherein the fragment of fibronectin is immobilized to an artificial substrate and comprises at least one domain selected from the group consisting of:

(a) a VLA-4 binding domain,

(b) a VLA-5 binding domain, and

(c) a heparin binding domain.

2. A method for expanding cytotoxic T cell having an antigen-specific cytotoxic activity, characterized in that the method comprises the steps of:

incubating a peripheral blood mononuclear cell with an antigen presenting cell in a medium containing effective ingredients consisting essentially of interleukin-2 and a fragment of fibronectin having a molecular weight of from 10 kDa to 180 kDa or a mixture thereof, wherein the fragment of fibronectin is immobilized to an artificial substrate and comprises at least one domain selected from the group consisting of (a) a VLA-4 binding domain (b) a VLA-5 binding domain and (c) a heparin binding domain, and said incubating step gives said peripheral blood mononuclear cell an ability to recognize a desired antigen and induces differentiation of the peripheral mononuclear cell to a cytotoxic T cell; and

incubating the cytotoxic T cell obtained by the preceding step in the presence of anti-CD3 antibody and a fragment of fibronectin having a molecular weight of from 10 kDa to 180 kDa or a mixture thereof, wherein the fragment of fibronectin is immobilized to an artificial substrate and is a fragment having at least one domain selected from the group consisting of:

(a) a VLA-4 binding domain,

(b) a VLA-5 binding domain, and

(c) a heparin binding domain.

3. The method according to claim 2 , wherein the cytotoxic T cell is incubated together with a feeder cell in said step.

4. The method according to claim 3 , wherein the feeder cell is a non-virus-infected cell.

5. A method for collecting cytotoxic T cell, comprising the step of selecting a cell population rich in cytotoxic T cell having an antigen-specific cytotoxic activity from a culture containing the cytotoxic T cell obtained by the method of claim 1 or 2 ; and collecting said cell population.

6. The method according to claim 1 , wherein the fragment of fibronectin comprises:

at least one of the amino acid sequences represented by SEQ ID NOS: 1 to 13.

7. The method according to claim 2 , wherein the fragment of fibronectin comprises:

at least one of the amino acid sequences represented by SEQ ID NOS: 1 to 13.

8. The method according to claim 1 , wherein the fragment of fibronectin is immobilized to a culture equipment or microbeads.

9. The method according to claim 2 , wherein the fragment of fibronectin is immobilized to a culture equipment or microbeads.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2004
From: SAGAWA, HIROAKI; IDENO, MITSUKO; KATO, IKUNOSHIN
To: TAKARA BIO INC.
Reel/Frame 015952/0571 →
Priority Claims (3)
JP 2001-246747 · Aug 15, 2001 · national
JP 2001-376966 · Dec 11, 2001 · national
JP 2002-084428 · Mar 25, 2002 · national
Continuity (1)
Related Publication 20050042208A1 · Feb 24, 2005